PREVIOUS QUESTION:

 

NEXT QUESTION:

 

How are luteinizing hormone-releasing hormone antagonists used to treat prostate cancer?

ANSWER

These drugs have been approved for use as hormone therapy in patients with advanced prostate cancer. Luteinizing hormone-releasing hormone (LHRH) antagonists lower testosterone levels more quickly than LHRH analogs. In addition, they don't cause a tumor flare (temporary rise in testosterone levels) as do LHRH analogs. Degarelix (Firmagon) is a LHRH antagonist used to treat advanced prostate cancer. It has been shown to decrease the progression of disease, but further trials are needed to look at long-term outcomes. It is fairly well tolerated with common side effects being local injection site problems and increased liver enzymes.

SOURCES: 

American Cancer Society. 

National Cancer Institute. 

Cancer Research UK.  

News release, Astellas Pharma Inc.

UpToDate.

Reviewed by Jennifer Robinson on July 24, 2018

SOURCES: 

American Cancer Society. 

National Cancer Institute. 

Cancer Research UK.  

News release, Astellas Pharma Inc.

UpToDate.

Reviewed by Jennifer Robinson on July 24, 2018

NEXT QUESTION:

How are antiandrogens used to treat prostate cancer?

WAS THIS ANSWER HELPFUL

THIS TOOL DOES NOT PROVIDE MEDICAL ADVICE. It is intended for general informational purposes only and does not address individual circumstances. It is not a substitute for professional medical advice, diagnosis or treatment and should not be relied on to make decisions about your health. Never ignore professional medical advice in seeking treatment because of something you have read on the WebMD Site. If you think you may have a medical emergency, immediately call your doctor or dial 911.

    This tool does not provide medical advice. See additional information.

    Other Answers On: